TY  - JOUR
AU  - Franklin, Cindy
AU  - Mohr, Peter
AU  - Bluhm, Leonie
AU  - Meier, Friedegund
AU  - Garzarolli, Marlene
AU  - Weichenthal, Michael
AU  - Kähler, Katharina
AU  - Grimmelmann, Imke
AU  - Gutzmer, Ralf
AU  - Utikal, Jochen
AU  - Terheyden, Patrick
AU  - Herbst, Rudolf
AU  - Haferkamp, Sebastian
AU  - Pfoehler, Claudia
AU  - Forschner, Andrea
AU  - Leiter, Ulrike
AU  - Ziller, Fabian
AU  - Meiss, Frank
AU  - Ulrich, Jens
AU  - Kreuter, Alexander
AU  - Gebhardt, Christoffer
AU  - Welzel, Julia
AU  - Schilling, Bastian
AU  - Kaatz, Martin
AU  - Scharfetter-Kochanek, Karin
AU  - Dippel, Edgar
AU  - Nashan, Dorothee
AU  - Sachse, Michael
AU  - Weishaupt, Carsten
AU  - Löffler, Harald
AU  - Gambichler, Thilo
AU  - Loquai, Carmen
AU  - Heinzerling, Lucie
AU  - Grabbe, Stephan
AU  - Debus, Dirk
AU  - Schley, Gaston
AU  - Hassel, Jessica C
AU  - Weyandt, Gerhard
AU  - Trommer, Maike
AU  - Lodde, Georg
AU  - Placke, Jan-Malte
AU  - Zimmer, Lisa
AU  - Livingstone, Elisabeth
AU  - Becker, Jürgen
AU  - Horn, Susanne
AU  - Schadendorf, Dirk
AU  - Ugurel, Selma
TI  - Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
JO  - Journal for ImmunoTherapy of Cancer
VL  - 11
IS  - 4
SN  - 2051-1426
CY  - London
PB  - BioMed Central
M1  - DKFZ-2023-00719
SP  - e005828
PY  - 2023
AB  - Despite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival outcomes dependent on the type of first-line therapy.Patients with metastatic, non-resectable melanoma (AJCCv8 stage IIIC-V) without brain metastasis at start of first-line therapy (1L-therapy) were identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were incidence of brain metastasis, brain metastasis-free survival (BMFS), progression-free survival (PFS), and overall survival (OS).Of 1704 patients, 916 were BRAF wild-type (BRAFwt) and 788 were BRAF V600 mutant (BRAFmut). Median follow-up time after start of 1L-therapy was 40.4 months. BRAFwt patients received 1L-therapy with immune checkpoint inhibitors (ICI) against CTLA-4+PD-1 (n=281) or PD-1 (n=544). In BRAFmut patients, 1L-therapy was ICI in 415 patients (CTLA-4+PD-1, n=108; PD-1, n=264), and BRAF+MEK targeted therapy (TT) in 373 patients. After 24 months, 1L-therapy with BRAF+MEK resulted in a higher incidence of brain metastasis compared with PD-1±CTLA-4 (BRAF+MEK, 30.3
KW  - melanoma (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37028819
DO  - DOI:10.1136/jitc-2022-005828
UR  - https://inrepo02.dkfz.de/record/275350
ER  -